Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vahagn Makaryan

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Expert Review of Hematology|November 18, 2023
The promise of novel treatments for severe chronic neutropeniaDavid C Dale, Audrey Anna Bolyard, Vahagn Makaryan
Journal of Cellular Immunology|September 2, 2022
Comparison of Gene Editing versus a Neutrophil Elastase Inhibitor as Potential Therapies for <i>ELANE</i> NeutropeniaVahagn Makaryan, Merideth Kelley, Breanna Fletcher, et al.
Journal of Cellular Immunology|January 27, 2025
Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for <i>ELANE</i> Associated NeutropeniaVahagn Makaryan, Merideth Kelley, Audrey Anna Bolyard, et al.
Current Opinion in Hematology|October 26, 2019
Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndromeDavid C Dale, Emily Dick, Merideth Kelley, et al.
Journal of Leukocyte Biology|July 30, 2017
Elastase inhibitors as potential therapies for <i>ELANE</i>-associated neutropeniaVahagn Makaryan, Merideth L Kelley, Breanna Fletcher, et al.
European Journal of Haematology|October 26, 2011
The cellular and molecular mechanisms for neutropenia in Barth syndromeVahagn Makaryan, Willem Kulik, Frederic M Vaz, et al.
Journal of Cellular Immunology|September 18, 2025
Modeling <i>TCIRG1</i> Neutropenia by Utilizing Patient Derived Induced Pluripotent Stem CellsVahagn Makaryan, Merideth L Kelley, Audrey Anna Bolyard, et al.
Blood|August 13, 2011
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndromeDavid C Dale, Audrey Anna Bolyard, Merideth L Kelley, et al.
Haematologica|May 4, 2006
Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern SwedenGöran Carlsson, Andrew A G Aprikyan, Kim Göransdotter Ericson, et al.
Blood|September 2, 2020
Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndromeDavid C Dale, Frank Firkin, Audrey Anna Bolyard, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Review of Hematology|November 18, 2023
The promise of novel treatments for severe chronic neutropeniaDavid C Dale, Audrey Anna Bolyard, Vahagn Makaryan
Journal of Cellular Immunology|September 2, 2022
Comparison of Gene Editing versus a Neutrophil Elastase Inhibitor as Potential Therapies for <i>ELANE</i> NeutropeniaVahagn Makaryan, Merideth Kelley, Breanna Fletcher, et al.
Journal of Cellular Immunology|January 27, 2025
Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for <i>ELANE</i> Associated NeutropeniaVahagn Makaryan, Merideth Kelley, Audrey Anna Bolyard, et al.
Current Opinion in Hematology|October 26, 2019
Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndromeDavid C Dale, Emily Dick, Merideth Kelley, et al.
Journal of Leukocyte Biology|July 30, 2017
Elastase inhibitors as potential therapies for <i>ELANE</i>-associated neutropeniaVahagn Makaryan, Merideth L Kelley, Breanna Fletcher, et al.
European Journal of Haematology|October 26, 2011
The cellular and molecular mechanisms for neutropenia in Barth syndromeVahagn Makaryan, Willem Kulik, Frederic M Vaz, et al.
Journal of Cellular Immunology|September 18, 2025
Modeling <i>TCIRG1</i> Neutropenia by Utilizing Patient Derived Induced Pluripotent Stem CellsVahagn Makaryan, Merideth L Kelley, Audrey Anna Bolyard, et al.
Blood|August 13, 2011
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndromeDavid C Dale, Audrey Anna Bolyard, Merideth L Kelley, et al.
Haematologica|May 4, 2006
Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern SwedenGöran Carlsson, Andrew A G Aprikyan, Kim Göransdotter Ericson, et al.
Blood|September 2, 2020
Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndromeDavid C Dale, Frank Firkin, Audrey Anna Bolyard, et al.
Pageof 2